{"id":"NCT01922739","sponsor":"Teva Branded Pharmaceutical Products R&D, Inc.","briefTitle":"Open-Label, Extension Study to Evaluate the Safety of Hydrocodone Bitartrate Extended-Release Tablets","officialTitle":"A 6-Month, Open-Label, Extension Study to Evaluate the Safety of Hydrocodone Bitartrate Extended-Release Tablets (CEP-33237) at 15 to 90 mg Every 12 Hours for Relief of Moderate to Severe Pain in Patients With Chronic Low Back Pain Who Require Opioid Treatment for an Extended Period of Time","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2013-07","primaryCompletion":"2014-08","completion":"2014-08","firstPosted":"2013-08-14","resultsPosted":"2017-06-02","lastUpdate":"2021-11-09"},"enrollment":182,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Low Back Pain"],"interventions":[{"type":"DRUG","name":"Hydrocodone ER","otherNames":["CEP-33237","Hydrocodone bitartrate extended-release tablets"]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"Hydrocodone ER","type":"EXPERIMENTAL"}],"summary":"This is a 6-month, nonrandomized, open-label extension study to assess the long-term safety of hydrocodone bitartrate extended-release (ER) tablets in patients with moderate to severe chronic low back pain who require continuous opioid treatment for an extended period of time.\n\nTo be eligible for Study 3104, patients were required to have completed the entire double blind treatment period on study drug (either placebo or hydrocodone bitartrate ER tablets) through week 12 of Study 3103 (NCT01789970) and to have met the entry criteria for Study 3104.","primaryOutcome":{"measure":"Participants With Adverse Events","timeFrame":"Day 1 of the Titration/Adjustment Period to Week 22 of the Treatment Period (total of 25-26 weeks)","effectByArm":[{"arm":"Placebo: Double-Blind Titration Period","deltaMin":4,"sd":null},{"arm":"Hydrocodone ER: Double-Blind Titration Period","deltaMin":2,"sd":null},{"arm":"Placebo: Open-Label Adjustment Period","deltaMin":34,"sd":null},{"arm":"Hydrocodone ER: Open-Label Adjustment Period","deltaMin":25,"sd":null},{"arm":"Hydrocodone ER: Open-Label Treatment Period","deltaMin":88,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":61,"countries":["United States"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":1,"n":182},"commonTop":["Nausea","Constipation"]}}